AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
decitabine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives | 790 | 2353-33-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.87 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 4.60 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 130 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.58 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 10 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 0 % | |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.724 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 9.354 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 1.936 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.250 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 94.870 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 95.780 | % | High | 1 |
| herg | hERG pIC50 | 3.265 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 0.989 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.192 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 91.190 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAPK7,NTRK1,NTRK2,PDK1,PDK2,PIK3CD,PRKDC | 21 | |||
| kinase-selectivity-class | PIK3CD | 1 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 5.082 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 0.914 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 97.420 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 2.065 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 95.410 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.799 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 97.130 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 93.330 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 897.429 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 2, 2006 | FDA | Astex Pharmaceuticals, Inc. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 413.10 | 34.97 | 181 | 3950 | 158168 | 90466148 |
| Myelosuppression | 391.11 | 34.97 | 130 | 4001 | 53461 | 90570855 |
| Neutropenia | 127.64 | 34.97 | 95 | 4036 | 224809 | 90399507 |
| Pneumonia | 105.84 | 34.97 | 137 | 3994 | 637922 | 89986394 |
| Off label use | 96.84 | 34.97 | 176 | 3955 | 1102076 | 89522240 |
| Disease progression | 90.60 | 34.97 | 67 | 4064 | 156548 | 90467768 |
| Thrombocytopenia | 89.89 | 34.97 | 75 | 4056 | 208650 | 90415666 |
| Pancytopenia | 89.42 | 34.97 | 60 | 4071 | 120203 | 90504113 |
| Acute myeloid leukaemia | 89.04 | 34.97 | 34 | 4097 | 20606 | 90603710 |
| Sepsis | 88.80 | 34.97 | 70 | 4061 | 179744 | 90444572 |
| Bone marrow failure | 87.25 | 34.97 | 38 | 4093 | 32183 | 90592133 |
| Acute myeloid leukaemia recurrent | 71.53 | 34.97 | 17 | 4114 | 2040 | 90622276 |
| Product use in unapproved indication | 71.40 | 34.97 | 82 | 4049 | 336154 | 90288162 |
| Death | 57.36 | 34.97 | 86 | 4045 | 456465 | 90167851 |
| Mucosal inflammation | 55.81 | 34.97 | 34 | 4097 | 57591 | 90566725 |
| Escherichia bacteraemia | 54.27 | 34.97 | 17 | 4114 | 5718 | 90618598 |
| Splenic abscess | 50.11 | 34.97 | 9 | 4122 | 269 | 90624047 |
| Pneumonia fungal | 46.92 | 34.97 | 16 | 4115 | 7015 | 90617301 |
| Posterior reversible encephalopathy syndrome | 46.68 | 34.97 | 22 | 4109 | 22317 | 90601999 |
| Respiratory failure | 45.66 | 34.97 | 40 | 4091 | 118378 | 90505938 |
| Haematotoxicity | 44.71 | 34.97 | 18 | 4113 | 12517 | 90611799 |
| Acute myeloid leukaemia refractory | 42.37 | 34.97 | 7 | 4124 | 126 | 90624190 |
| Pyrexia | 40.22 | 34.97 | 91 | 4040 | 660394 | 89963922 |
| Platelet count decreased | 37.00 | 34.97 | 38 | 4093 | 136931 | 90487385 |
| Leukaemia recurrent | 35.20 | 34.97 | 9 | 4122 | 1458 | 90622858 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 430.57 | 29.83 | 173 | 5654 | 40288 | 42575220 |
| Febrile neutropenia | 314.91 | 29.83 | 234 | 5593 | 185469 | 42430039 |
| Acute myeloid leukaemia | 134.32 | 29.83 | 64 | 5763 | 22192 | 42593316 |
| Neutropenia | 117.41 | 29.83 | 140 | 5687 | 199291 | 42416217 |
| Off label use | 105.97 | 29.83 | 253 | 5574 | 638082 | 41977426 |
| Pancytopenia | 92.08 | 29.83 | 96 | 5731 | 117647 | 42497861 |
| Infection | 90.55 | 29.83 | 93 | 5734 | 111975 | 42503533 |
| Acute myeloid leukaemia recurrent | 90.48 | 29.83 | 29 | 5798 | 3483 | 42612025 |
| Bone marrow failure | 89.64 | 29.83 | 56 | 5771 | 33037 | 42582471 |
| Thrombocytopenia | 88.70 | 29.83 | 119 | 5708 | 190160 | 42425348 |
| Pneumonia | 70.28 | 29.83 | 168 | 5659 | 421981 | 42193527 |
| Sepsis | 63.05 | 29.83 | 104 | 5723 | 199230 | 42416278 |
| Bacteraemia | 61.87 | 29.83 | 40 | 5787 | 25000 | 42590508 |
| Cytopenia | 58.72 | 29.83 | 34 | 5793 | 17463 | 42598045 |
| Product use in unapproved indication | 55.31 | 29.83 | 94 | 5733 | 184362 | 42431146 |
| Disease progression | 55.17 | 29.83 | 82 | 5745 | 143574 | 42471934 |
| Acute myeloid leukaemia refractory | 52.83 | 29.83 | 10 | 5817 | 127 | 42615381 |
| Drug ineffective | 47.36 | 29.83 | 190 | 5637 | 630007 | 41985501 |
| Therapy partial responder | 47.05 | 29.83 | 31 | 5796 | 19990 | 42595518 |
| Therapy non-responder | 42.48 | 29.83 | 44 | 5783 | 53315 | 42562193 |
| Pyrexia | 36.25 | 29.83 | 127 | 5700 | 393915 | 42221593 |
| Mucormycosis | 32.57 | 29.83 | 17 | 5810 | 7126 | 42608382 |
| Aspergillus infection | 31.21 | 29.83 | 22 | 5805 | 15815 | 42599693 |
| Oesophageal candidiasis | 30.32 | 29.83 | 15 | 5812 | 5620 | 42609888 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 708.18 | 29.28 | 398 | 9006 | 316369 | 110263526 |
| Myelosuppression | 583.11 | 29.28 | 239 | 9165 | 94101 | 110485794 |
| Neutropenia | 227.25 | 29.28 | 214 | 9190 | 374406 | 110205489 |
| Acute myeloid leukaemia recurrent | 206.70 | 29.28 | 54 | 9350 | 5085 | 110574810 |
| Acute myeloid leukaemia | 196.28 | 29.28 | 85 | 9319 | 38025 | 110541870 |
| Pneumonia | 190.75 | 29.28 | 297 | 9107 | 876417 | 109703478 |
| Bone marrow failure | 174.00 | 29.28 | 89 | 9315 | 57759 | 110522136 |
| Thrombocytopenia | 164.59 | 29.28 | 174 | 9230 | 348711 | 110231184 |
| Product use in unapproved indication | 159.76 | 29.28 | 193 | 9211 | 447184 | 110132711 |
| Sepsis | 159.28 | 29.28 | 166 | 9238 | 327180 | 110252715 |
| Pancytopenia | 154.86 | 29.28 | 134 | 9270 | 209479 | 110370416 |
| Off label use | 137.66 | 29.28 | 354 | 9050 | 1499831 | 109080064 |
| Disease progression | 126.25 | 29.28 | 128 | 9276 | 243906 | 110335989 |
| Cytopenia | 89.52 | 29.28 | 46 | 9358 | 30070 | 110549825 |
| Acute myeloid leukaemia refractory | 81.09 | 29.28 | 15 | 9389 | 277 | 110579618 |
| Bacteraemia | 79.98 | 29.28 | 48 | 9356 | 42342 | 110537553 |
| Haematotoxicity | 79.91 | 29.28 | 38 | 9366 | 21044 | 110558851 |
| Infection | 77.18 | 29.28 | 122 | 9282 | 362078 | 110217817 |
| Therapy partial responder | 75.24 | 29.28 | 44 | 9360 | 37017 | 110542878 |
| Drug ineffective | 65.30 | 29.28 | 278 | 9126 | 1520262 | 109059633 |
| Mucosal inflammation | 63.95 | 29.28 | 58 | 9346 | 96083 | 110483812 |
| Pneumonia fungal | 63.37 | 29.28 | 29 | 9375 | 14725 | 110565170 |
| Pyrexia | 62.07 | 29.28 | 192 | 9212 | 898073 | 109681822 |
| Respiratory failure | 60.98 | 29.28 | 83 | 9321 | 215249 | 110364646 |
| Leukaemia recurrent | 58.13 | 29.28 | 18 | 9386 | 3113 | 110576782 |
| Death | 53.51 | 29.28 | 155 | 9249 | 698714 | 109881181 |
| Anaemia | 51.53 | 29.28 | 131 | 9273 | 546955 | 110032940 |
| Escherichia bacteraemia | 50.10 | 29.28 | 22 | 9382 | 10142 | 110569753 |
| Septic shock | 49.63 | 29.28 | 64 | 9340 | 157464 | 110422431 |
| Aspergillus infection | 48.29 | 29.28 | 29 | 9375 | 25587 | 110554308 |
| Platelet count decreased | 48.15 | 29.28 | 77 | 9327 | 230366 | 110349529 |
| Therapy non-responder | 48.13 | 29.28 | 63 | 9341 | 157244 | 110422651 |
| Mucormycosis | 42.86 | 29.28 | 20 | 9384 | 10608 | 110569287 |
| Tumour lysis syndrome | 41.00 | 29.28 | 28 | 9376 | 30773 | 110549122 |
| Organising pneumonia | 40.14 | 29.28 | 21 | 9383 | 14222 | 110565673 |
| Drug ineffective for unapproved indication | 39.19 | 29.28 | 46 | 9358 | 102792 | 110477103 |
| Pain | 37.84 | 29.28 | 17 | 9387 | 954938 | 109624957 |
| Graft versus host disease | 37.30 | 29.28 | 22 | 9382 | 18784 | 110561111 |
| Bronchopulmonary aspergillosis | 37.05 | 29.28 | 26 | 9378 | 29837 | 110550058 |
| Chronic graft versus host disease | 35.69 | 29.28 | 17 | 9387 | 9440 | 110570455 |
| Neutrophil count decreased | 34.77 | 29.28 | 47 | 9357 | 120894 | 110459001 |
| Disease recurrence | 33.39 | 29.28 | 33 | 9371 | 60751 | 110519144 |
| Splenic abscess | 33.05 | 29.28 | 9 | 9395 | 991 | 110578904 |
| Gene mutation | 32.91 | 29.28 | 12 | 9392 | 3417 | 110576478 |
| Pseudomonas infection | 31.68 | 29.28 | 23 | 9381 | 27830 | 110552065 |
| Cardiac failure | 30.35 | 29.28 | 56 | 9348 | 187570 | 110392325 |
| Headache | 30.11 | 29.28 | 19 | 9385 | 882358 | 109697537 |
| Malignant neoplasm progression | 29.37 | 29.28 | 53 | 9351 | 174514 | 110405381 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01BC08 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ANTIMETABOLITES Pyrimidine analogues |
| ATC | L01BC58 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ANTIMETABOLITES Pyrimidine analogues |
| FDA MoA | N0000000233 | Nucleic Acid Synthesis Inhibitors |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D000964 | Antimetabolites, Antineoplastic |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| FDA EPC | N0000175595 | Nucleoside Metabolic Inhibitor |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Related Drugs by ATC class:
L01BC Pyrimidine analogues 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute myeloid leukemia, disease | indication | 91861009 | |
| Myelodysplastic syndrome | indication | 109995007 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.94 | acidic |
| pKa2 | 13.68 | acidic |
| pKa3 | 4.39 | Basic |
| pKa4 | 2.93 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | 8618075 | Oct. 16, 2028 | METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE |
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | 8618075 | Oct. 16, 2028 | METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE |
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | 8268800 | Aug. 22, 2030 | METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE |
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | 8268800 | Aug. 22, 2030 | METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE |
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | 8268800 | Aug. 22, 2030 | TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA |
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | 8268800 | Aug. 22, 2030 | TREATMENT OF MYELODYSPLASTIC SYNDROME |
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | 12239653 | Feb. 24, 2041 | TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA |
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | 12239653 | Feb. 24, 2041 | TREATMENT OF MYELODYSPLASTIC SYNDROME |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | July 7, 2027 | TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS. |
| 100MG;35MG | INQOVI | TAIHO ONCOLOGY | N212576 | July 7, 2020 | RX | TABLET | ORAL | May 13, 2029 | IN COMBINATION WITH VENETOCLAX FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA (cytosine-5)-methyltransferase 1 | Enzyme | INHIBITOR | IC50 | 7.52 | CHEMBL | CHEMBL | |||
| DNA (cytosine-5)-methyltransferase 3A | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4025438 | VUID |
| N0000179023 | NUI |
| D03665 | KEGG_DRUG |
| 879492-57-6 | SECONDARY_CAS_RN |
| 15657 | RXNORM |
| 4025438 | VANDF |
| C0049065 | UMLSCUI |
| CHEBI:50131 | CHEBI |
| CHEMBL1201129 | ChEMBL_ID |
| DB01262 | DRUGBANK_ID |
| D000077209 | MESH_DESCRIPTOR_UI |
| 451668 | PUBCHEM_CID |
| 6805 | IUPHAR_LIGAND_ID |
| 6374 | INN_ID |
| 776B62CQ27 | UNII |
| 203877 | MMSL |
| 21366 | MMSL |
| 81707 | MMSL |
| d05788 | MMSL |
| 011499 | NDDF |
| 420517007 | SNOMEDCT_US |
| 420759005 | SNOMEDCT_US |
| 776B62CQ27 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 28 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-224 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-219 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 28 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-304 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-427 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| DECITABINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-430 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55111-556 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| Decitabine | Human Prescription Drug Label | 1 | 55150-376 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| INQOVI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64842-0727 | TABLET, FILM COATED | 35 mg | ORAL | NDA | 32 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67184-0535 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 28 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-316 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| DECITABINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-573 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-618 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 28 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-642 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| decitabine | Human Prescription Drug Label | 1 | 68083-528 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-738 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1644 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 28 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-119 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-119 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| Decitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72162-2634 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| Decitabine | Human Prescription Drug Label | 1 | 72205-031 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| Decitabine | Human Prescription Drug Label | 1 | 72205-036 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| Decitabine | Human Prescription Drug Label | 1 | 72603-107 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
| DECITABINE | Human Prescription Drug Label | 1 | 75834-190 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |